Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 12,075 shares, a growth of 70.8% from the October 15th total of 7,070 shares. Based on an average daily volume of 8,654 shares, the days-to-cover ratio is currently 1.4 days. Approximately 0.2% of the shares of the company are sold short.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP boosted its stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) by 40.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,064 shares of the company’s stock after purchasing an additional 4,046 shares during the period. Susquehanna International Group LLP owned about 0.17% of Cryo-Cell International worth $45,000 at the end of the most recent quarter. Institutional investors own 10.44% of the company’s stock.
Cryo-Cell International Trading Down 6.2%
NYSEAMERICAN CCEL traded down $0.30 during trading on Monday, reaching $4.55. The company’s stock had a trading volume of 22,061 shares, compared to its average volume of 15,681. The firm has a 50 day moving average price of $4.47 and a 200 day moving average price of $3.76. Cryo-Cell International has a 12 month low of $2.72 and a 12 month high of $5.45. The firm has a market capitalization of $36.67 million, a price-to-earnings ratio of -19.78 and a beta of 0.45.
Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last issued its quarterly earnings results on Friday, October 9th. The company reported $0.16 earnings per share (EPS) for the quarter. The company had revenue of $7.82 million during the quarter.
Cryo-Cell International Company Profile
Cryo-Cell International provides stem cell processing and cryogenic storage services, primarily for families preserving cells collected at childbirth. Its core services include processing and storing umbilical cord blood and cord tissue for potential future medical use. Founded in 1989, the company is based in Oldsmar, Florida, and is among the early private cord blood banking businesses in the United States. It serves customers in the U.S. and reaches international markets through distribution relationships.
See Also
- Five stocks we like better than Cryo-Cell International
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
